A randomized trial to optimize HIV/TB care in South Africa: design of the Sizanani trial

BMC Infectious Diseases

Elena Losina²  Rochelle P Walensky²  Jeffrey N Katz³  Kenneth A Freedberg²  Alison Erlwanger⁵  Marion Robine⁵  Tessa Govender¹  Sharon M Coleman⁴  Laura M Bogart⁶  Douglas Ross⁷  Christine E Chaisson⁴  Janet Giddy¹  Ingrid V Bassett² 

[1] McCord Hospital, Durban, South Africa;Harvard University Center for AIDS Research, Harvard University, Cambridge, MA, USA;Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, USA;Data Coordinating Center, Boston University School of Public Health, Boston, MA, USA;Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA;Division of General Pediatrics, Department of Medicine, Boston, Children’s Hospital, Boston, MA, USA;St. Mary’s Hospital, Mariannhill, Durban, South Africa

关键词: Counseling/Support;    Randomized controlled trial;    SMS reminders;    Linkage to care;    South Africa;    Tuberculosis;    (3-10): HIV/AIDS;   

Others  :  1145937
DOI  :  10.1186/1471-2334-13-390

 received in 2013-08-08, accepted in 2013-08-20,  发布年份 2013

【 摘 要 】

Background

Despite increases in HIV testing, only a fraction of people newly diagnosed with HIV infection enter the care system and initiate antiretroviral therapy (ART) in South Africa. We report on the design and initial enrollment of a randomized trial of a health system navigator intervention to improve linkage to HIV care and TB treatment completion in Durban, South Africa.

Methods/Design

We employed a multi-site randomized controlled trial design. Patients at 4 outpatient sites were enrolled prior to HIV testing. For all HIV-infected participants, routine TB screening with sputum for mycobacterial smear and culture were collected. HIV-infected participants were randomized to receive the health system navigator intervention or usual care. Participants in the navigator arm underwent a baseline interview using a strengths-based case management approach to assist in identifying barriers to entering care and devising solutions to best cope with perceived barriers. Over 4 months, participants in the navigator arm received scheduled phone and text messages. The primary outcome of the study is linkage and retention in care, assessed 9 months after enrollment. For ART-eligible participants without TB, the primary outcome is 3 months on ART as documented in the medical record; participants co-infected with TB are also eligible to meet the primary outcome of completion of 6 months of TB treatment, as documented by the TB clinic. Secondary outcomes include mortality, receipt of CD4 count and TB test results, and repeat CD4 counts for those not ART-eligible at baseline. We hypothesize that a health system navigator can help identify and positively affect modifiable patient factors, including self-efficacy and social support, that in turn can improve linkage to and retention in HIV and TB care.

Discussion

We are currently evaluating the clinical impact of a novel health system navigator intervention to promote entry to and retention in HIV and TB care for people newly diagnosed with HIV. The details of this study protocol will inform clinicians, investigators, and policy makers of strategies to best support HIV-infected patients in resource-limited settings.

Trial registration

Clinicaltrials.gov. unique identifier:NCT01188941.

【 授权许可】

   
2013 Bassett et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]UNAIDS: HIV and AIDS estimates. 2011. [http://www.unaids.org/en/regionscountries/countries/southafrica/ webcite]
• [2]World Health Organization: Global tuberculosis report 2012. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf webcite
• [3]World Health Organization: Epidemiological country profiles - HIV & AIDS. South Africa; 2008. [ http://www.afro.who.int/en/clusters-a-programmes/dpc/acquired-immune-deficiency-syndrome/aids-country-profiles.html webcite]
• [4]Lawn SD, Harries AD, Anglaret X, Myer L, Wood R: Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:1897-1908.
• [5]Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R: Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006, 43:770-776.
• [6]Losina E, Bassett IV, Giddy J, Chetty S, Regan S, Walensky RP, Ross D, Scott CA, Uhler LM, Katz JN, Holst H, Freedberg KA: The “ART” of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One 2010, 5:e9538.
• [7]World Health Organization: TB /HIV facts 2011-2012. http://www.who.int/tb/publications/TBHIV_Facts_for_2011.pdf webcite
• [8]Khumalo-Sakutukwa G, Morin SF, Fritz K, Charlebois ED, Van Rooyen H, Chingono A, Modiba P, Mrumbi K, Visrutaratna S, Singh B, Sweat M, Celentano DD, Coates TJ: Project accept (HPTN 043): a community-based intervention to reduce HIV incidence in populations at risk for HIV in sub-Saharan Africa and Thailand. J Acquir Immune Defic Syndr 2008, 49:422-431.
• [9]Govindasamy D, Ford N, Kranzer K: Risk factors, barriers and facilitators for linkage to art care in sub-saharan africa: a systematic review. AIDS 2012, 26:2059-2067.
• [10]Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, De Walque D, MacKeen L, Haberer J, Kimaiyo S, Sidle J, Ngare D, Bangsberg DR: Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS 2011, 25:825-834.
• [11]Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N: Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load: a meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr 2006, 43(Suppl 1):S23-S35.
• [12]Harries AD, Zachariah R, Lawn SD, Rosen S: Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010, 15(Suppl 1):70-75.
• [13]Kushel MB, Colfax G, Ragland K, Heineman A, Palacio H, Bangsberg DR: Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. Clin Infect Dis 2006, 43:234-242.
• [14]Mannheimer SB, Morse E, Matts JP, Andrews L, Child C, Schmetter B, Friedland GH: Sustained benefit from a long-term antiretroviral adherence intervention: results of a large randomized clinical trial. J Acquir Immune Defic Syndr 2006, 43(Suppl 1):S41-S47.
• [15]Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, Del Rio C, Strathdee S, Sansom SL, Siegal HA, Greenberg AE, Holmberg SD: Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS 2005, 19:423-431.
• [16]Craw JA, Gardner LI, Marks G, Rapp RC, Bosshart J, Duffus WA, Rossman A, Coughlin SL, Gruber D, Safford LA, Overton J, Schmitt K: Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. J Acquir Immune Defic Syndr 2008, 47:597-606.
• [17]Andersen RM: Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995, 36:1-10.
• [18]Andersen R, Newman JF: Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc 1973, 51:95-124.
• [19]Saleebey D: The strengths perspective in social work practice. 5th edition. Boston: Allyn & Bacon; 2009.
• [20]South Africa National Department of Health: Clinical GUIDELINES for the management of HIV & AIDS in adults and adolescents. 2010. http://www.fidssa.co.za/Guidelines/2010_Adult_ART_Guidelines.pdf webcite
• [21]Rajabiun S, Mallinson RK, McCoy K, Coleman S, Drainoni ML, Rebholz C, Holbert T: “Getting me back on track”: the role of outreach interventions in engaging and retaining people living with HIV/AIDS in medical care. AIDS Patient Care STDS 2007, 21(Suppl 1):S20-S29.
• [22]NIH Office of Extramural Research: Protecting human research participants. http://phrp.nihtraining.com/users/login.php webcite
• [23]Bassett IV, Giddy J, Nkera J, Wang B, Losina E, Lu Z, Freedberg KA, Walensky RP: Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr 2007, 46(2):181-186.
• [24]Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, Holst H, Ross D, Katz JN, Walensky RP, Freedberg KA, Losina E: Who starts antiretroviral therapy in Durban, South Africa?… not everyone who should. AIDS 2010, 24(Suppl 1):S37-S44.
• [25]Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, Walensky RP, Freedberg KA: Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010, 51:823-829.
• [26]Republic of South Africa Department of Health: Global aids response progress report 2012. http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_ZA_Narrative_Report.pdf webcite
• [27]Clouse K, Pettifor AE, Maskew M, Bassett J, Van Rie A, Behets F, Gay C, Sanne I, Fox MP: Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2013, 62:e39-e46.
• [28]IRIN humanitarian news and analysis. South Africa: National HIV testing campaign disappoints; 2010. http://www.irinnews.org/Report/90410/SOUTH-AFRICA-National-HIV-testing-campaign-disappoints webcite
• [29]Fox MP, Rosen S: Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010, 15(Suppl 1):1-15.
• [30]Kranzer K, Govindasamy D, Ford N, Johnston V, Lawn SD: Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc 2012, 15:17383.
• [31]Barnighausen T, Tanser F, Dabis F, Newell ML: Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence. Curr Opin HIV AIDS 2012, 7:140-150.
• [32]Mills EJ, Lester R, Ford N: Adherence to antiretroviral therapy: supervision or support? Lancet Infect Dis 2012, 12:97-98.
• [33]Bassett IV, Chetty S, Wang B, Mazibuko M, Giddy J, Lu Z, Walensky RP, Freedberg KA, Losina E: Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa. J Acquir Immune Defic Syndr 2012, 59:25-30.
• [34]Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD: Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One 2013, 8:e55824.
• [35]Mystakidou K, Panagiotou I, Katsaragakis S, Tsilika E, Parpa E: Ethical and practical challenges in implementing informed consent in HIV/AIDS clinical trials in developing or resource-limited countries. SAHARA J 2009, 6:46-57.
• [36]Bendavid E, Brandeau ML, Wood R, Owens DK: Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med 2010, 170:1347-1354.
• [37]Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48-57.
• [38]Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, De Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, et al.: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505.
• [39]Jia Z, Ruan Y, Li Q, Xie P, Li P, Wang X, Chen RY, Shao Y: Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet 2012. http://dx.doi.org/10.1016/S0140-6736(12)61898-4 webcite
• [40]Cloete C, Regan S, Giddy J, Erlwanger A, Freedberg KA, Walensky RP, Losina E, Bassett IV: Large-scale, rapid transfer of HIV-infected patients from hospital-based to primary health clinics in South Africa: an assessment of self-reported linkage to care [Abstract]. Miami Fl: 8th International conference on HIV Treatment and Prevention Adherence; 2013.